Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-09-01
DOI
https://doi.org/10.3389/fimmu.2025.1667785
Citations
1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
1.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study

Yan Li, Hang Yuan, Hong-Tao Hu, Ke Zhao et al.
1 citations
Frontiers in Immunology
Hepatocellular Carcinoma Treatment and Prognosis
1.32
article

Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study

Yan Li, Hang Yuan, Hong-Tao Hu, Ke Zhao, Quan-Jun Yao, Yanan Zhao, Lifeng Wang, Ho-Young Song, Xiang Geng
article en
1 citations

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
Henan Cancer Hospital (CN)
Natural Science Foundation of Henan Province
Openalex Percentile: Top 17%
Hepatocellular Carcinoma Treatment and Prognosis
1.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.